Ready to Compete with Global Companies
SK Plasma, a company specializing in blood products, said on Oct. 30 that its new factory in Andong, North Gyeongsang Province, has started full-scale commercial production.
SK Plasma invested about 150 billion won to build a new plant at the Bioindustry Complex in Andong to expand the supply of blood products.
Considering the characteristics of blood products that are sensitive to external contamination, this plant has introduced a central remote control system and automatic washing system and increased efficiency by separating production lines by product. In addition, it has unified all processes necessary to manufacture products from raw materials storage to sorting, refining, processing, packaging, and quality control.
The company stressed that it has also completed preparations for future overseas expansion by using equipment that meets the European standard for manufacturing and management of leading drugs. Based on this, it received GMP certification from South Korea's Ministry of Food and Drug Safety in August.
SK Plasma has secured 600,000 liters of blood products annually through its new plant in Andong, which is about 500 percent more than before. The plant will produce a total of six blood products, including albumin and immunogloblin.
"The new plant allows us to supply blood products stably in South Korea and to compete against global businesses in overseas markets," said SK Plazma CEO Jeon Gwang-hyeon.